A technology platform for discovery and design of bispecific fusion protein. Antibody molecules were prepared by monoclonal antibody screening, identification and optimization；and then dual-target drugs were constructed. In order to obtain preclinical PCC candidates, fusion protein molecules were further selected by in vitro functional study of T cell immune response and in vivo efficacy in various mouse models, including humanized and transgenic mice.